Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Adaptive designs for randomized trials in public health.

Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD.

Annu Rev Public Health. 2009;30:1-25. doi: 10.1146/annurev.publhealth.031308.100223. Review.

2.

Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.

Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, Harris S.

Clin Trials. 2012 Dec;9(6):671-80. doi: 10.1177/1740774512461859.

3.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

4.

Accrual to cancer clinical trials: directions from the research literature.

Gotay CC.

Soc Sci Med. 1991;33(5):569-77. Review.

PMID:
1962228
5.

Panel discussion 1.

Dickersin K, Williams G, George S.

Clin Trials. 2012 Dec;9(6):696-704. doi: 10.1177/1740774512463179. No abstract available.

PMID:
23250943
6.

Adaptive Bayesian randomized trials: realizing their potential.

Pullenayegum EM.

J Bone Joint Surg Am. 2012 Jul 18;94 Suppl 1:29-33. doi: 10.2106/JBJS.L.00094.

PMID:
22810444
7.

Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.

Privitera M.

Epilepsy Res. 2006 Jan;68(1):52-6. Review.

PMID:
16377139
8.
9.

Response-adaptive decision-theoretic trial design: operating characteristics and ethics.

Lipsky AM, Lewis RJ.

Stat Med. 2013 Sep 20;32(21):3752-65. doi: 10.1002/sim.5807. Epub 2013 Apr 4.

10.

Interventions to prevent misconduct and promote integrity in research and publication.

Marusic A, Wager E, Utrobicic A, Rothstein HR, Sambunjak D.

Cochrane Database Syst Rev. 2016 Apr 4;4:MR000038. doi: 10.1002/14651858.MR000038.pub2. Review.

PMID:
27040721
11.

Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems.

Anderson ML, Califf RM, Sugarman J; participants in the NIH Health Care Systems Research Collaboratory Cluster Randomized Trial Workshop.

Clin Trials. 2015 Jun;12(3):276-86. doi: 10.1177/1740774515571140. Epub 2015 Mar 1.

12.

Design issues in randomized phase II/III trials.

Korn EL, Freidlin B, Abrams JS, Halabi S.

J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.

13.

Dynamic wait-listed designs for randomized trials: new designs for prevention of youth suicide.

Brown CH, Wyman PA, Guo J, Peña J.

Clin Trials. 2006;3(3):259-71.

PMID:
16895043
14.

Costs of clinical trials and the need for efficiency: a brief overview.

Friedewald WT.

Stat Med. 1990 Jan-Feb;9(1-2):9-12. No abstract available.

PMID:
2345842
15.

Designing a cost-effective clinical trial.

Hornberger JC, Brown BW Jr, Halpern J.

Stat Med. 1995 Oct 30;14(20):2249-59.

PMID:
8552901
16.
17.

[Controlled randomized clinical trials].

Jaillon P.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8. French.

PMID:
18225427
18.

Ethics and practice: alternative designs for phase III randomized clinical trials.

Palmer CR, Rosenberger WF.

Control Clin Trials. 1999 Apr;20(2):172-86.

PMID:
10227416
19.
20.

A Bayesian decision-theoretic sequential response-adaptive randomization design.

Jiang F, Jack Lee J, Müller P.

Stat Med. 2013 May 30;32(12):1975-94. doi: 10.1002/sim.5735. Epub 2013 Jan 13.

Supplemental Content

Support Center